Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | FLT3 amp |
Therapy | Sunitinib |
Indication/Tumor Type | colorectal cancer |
Response Type | no benefit |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FLT3 amp | colorectal cancer | no benefit | Sunitinib | Phase II | Actionable | In a Phase II trial (TAPUR), treatment with Sutent (sunitinib) did not demonstrate clinical activity in patients with colorectal cancer with FLT3 amplification (n=10), resulting in no objective responses and stable disease at 16 weeks in 2 patients (PMID: 33068284; NCT02693535). | 33068284 |
PubMed Id | Reference Title | Details |
---|---|---|
(33068284) | Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. | Full reference... |